CanSino Biologics, Inc. Class H (HK:6185) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CanSino Biologics Inc. announced that its supplemental drug application to expand the age range for its Menhycia vaccine has been accepted by China’s National Medical Products Administration. This move is expected to enhance the company’s market presence, as it continues to experience strong revenue growth, with a 39.07% increase in sales of meningococcal vaccines in the first three quarters of 2024 compared to the previous year. Investors may find this development promising as CanSino strengthens its competitive edge in the vaccine industry.
For further insights into HK:6185 stock, check out TipRanks’ Stock Analysis page.